Ocular Therapeutix Drops 10.71% on Earnings Miss

Ocular Therapeutix, Inc. (NASDAQ: OCUL) shares dropped 10.71% in pre-market trading on August 27, 2025, reflecting significant investor sentiment shifts.

Vanguard Group Inc. reduced its holdings in Ocular Therapeutix by 1.4% during the first quarter, selling 119,398 shares. This move, along with adjustments by other institutional investors, indicates a mixed outlook on the company's future performance. Vontobel Holding Ltd. acquired a new position, while GAMMA Investing LLC, Rhumbline Advisers, ProShare Advisors LLC, and Ameriprise Financial Inc. all increased their stakes in the biopharmaceutical company.

Analysts have also weighed in on Ocular Therapeutix, with Scotiabank lowering their target price to $20.00 and maintaining a "sector outperform" rating. HC Wainwright and Needham & Company LLC both issued "buy" ratings with target prices of $15.00. The consensus rating among analysts is a "Buy" with a target price of $17.20.

Ocular Therapeutix reported earnings per share (EPS) of ($0.39) for the quarter, missing analysts' estimates of ($0.35). The company's revenue for the quarter was $13.46 million, slightly above expectations of $13.12 million. However, the negative net margin of 382.51% and return on equity of 71.92% indicate ongoing financial challenges. The company's revenue declined by 17.7% year-over-year, raising concerns about its financial health.